As for S100B, it is a valuable serum biomarker in the follow‐up of stage III and IV melanoma patients,63 particularly in early detection of progressive disease as well as in the prediction response to BRAF inhibitors and anti‐programmed cell death protein 1 (PD‐1) therapy.64, 65, 66. Here, BRAF is linked to melanoma.